Ger­man drug­mak­er files $21.6M IPO for skin can­cer drug

Ger­man biotech Biofron­tera is look­ing to raise $21.6 mil­lion in a US IPO to fund de­vel­op­ment and mar­ket­ing of its late-stage skin care drug.

The com­pa­ny is the mak­er of Ameluz (amino­lae­vulin­ic acid), ap­proved by the FDA in com­bi­na­tion with a med­ical de­vice for the skin can­cer pre­cur­sor ac­tinic ker­ato­sis. Now, Biofron­tera aims to ex­pand its la­bel so it can be used in su­per­fi­cial basal cell car­ci­no­ma, a form of squa­mous cell car­ci­no­ma called Bowen’s dis­ease, and larg­er treat­ment ar­eas of ac­tinic ker­ato­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.